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Abstract: Elevated low-density lipoprotein (LDL) cholesterol and lowered high-density 
lipoprotein (HDL) cholesterol are important risk factors for cardiovascular disease. Accordingly, 
raising HDL cholesterol induced by cholesteryl ester transfer protein (CETP) inhibition is an 
attractive approach for reducing the residual risk of cardiovascular events that persist in many 
patients receiving low-density LDL cholesterol-lowering therapy with statins. The development 
of torcetrapib, a CETP inhibitor, was terminated due to its adverse cardiovascular effects. 
These adverse effects did not influence the mechanism of CETP inhibition, but affected the 
molecule itself. Therefore a CETP modulator, dalcetrapib, and a CETP inhibitor, anacetrapib, 
are in Phase III of clinical trials to evaluate their effects on cardiovascular outcomes. In the 
dal-VESSEL (dalcetrapib Phase IIb endothelial function study) and the dal-PLAQUE (safety 
and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality 
imaging) clinical studies, dalcetrapib reduced CETP activity by 50% and increased HDL 
cholesterol levels by 31% without changing LDL cholesterol levels. Moreover, dalcetrapib 
was associated with a reduction in carotid vessel-wall inflammation at 6 months, as well as a 
reduced vessel-wall area at 24 months compared with the placebo. In the DEFINE (determining 
the efficacy and tolerability of CETP inhibition with anacetrapib) clinical study, anacetrapib 
increased HDL cholesterol levels by 138% and decreased LDL cholesterol levels by 36%. In 
contrast with torcetrapib, anacetrapib had no adverse cardiovascular effects. The potential of 
dalcetrapib and anacetrapib in the treatment of cardiovascular diseases will be revealed by two 
large-scale clinical trials, the dal-OUTCOMES (efficacy and safety of dalcetrapib in patients 
with recent acute coronary syndrome) study and the REVEAL (randomized evaluation of the 
effects of anacetrapib through lipid modification, a large-scale, randomized placebo-controlled 
trial of the clinical effects of anacetrapib among people with established vascular disease) study. 
The dal-OUTCOMES study is testing whether dalcetrapib can reduce cardiovascular events 
and the REVEAL study is testing whether anacetrapib can reduce cardiovascular events. These 
reports are expected to be released by 2013 and 2017, respectively.
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Introduction
Cardiovascular disease remains the most common cause of morbidity and 
  mortality despite the significant reduction of cardiovascular events with the use of 
hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins) that lower low-
density lipoprotein (LDL) cholesterol.1 A low level of high-density lipoprotein (HDL) 
cholesterol is another critical risk factor for cardiovascular events independent of LDL 
cholesterol levels, and an inverse relationship is observed between HDL cholesterol and 
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the risk of cardiovascular disease.2–4 Moreover, higher levels 
of HDL cholesterol are associated with reduced plaque pro-
gression and reduced frequency of cardiovascular events.5,6 
Therefore, raising HDL cholesterol is considered an attractive 
target for cardiovascular-risk lowering strategies. However, 
current HDL cholesterol-elevating drugs (fibrates and niacin) 
have limited efficacy and undesirable side effects.7,8
Cholesteryl ester transfer protein (CETP) is a plasma 
glycoprotein that is bound mainly to HDL particles, primarily 
HDL3 subclass, and transfers cholesteryl ester (CE) and 
triglyceride (TG) between circulating lipoproteins.9,10 CETP 
mediates the heterotypic transfer of neutral lipids (CE and 
TG) between HDL and apolipoprotein B (apoB)-containing 
lipoproteins (such as LDL and VLDL) as well as the 
homotypic transfer of CE among HDL subparticles (HDL3, 
HDL2, and pre-β HDL) (Figure 1). Since the net transfer of 
CE is from HDL to apoB-containing lipoproteins according 
to the concentration gradient, CETP is noted as an attractive 
target for raising HDL cholesterol.11–13 Indeed, the inhibition 
of CETP raises plasma HDL cholesterol levels.14–18 However, 
raised HDL cholesterol induced by CETP inhibition leads to 
an increase in cholesterol clearance via the HDL-mediated 
reverse cholesterol transport (RCT) pathway, which 
transfers excess cholesterol from the macrophages in the 
atherosclerotic lesions to the liver for excretion into bile. The 
dynamics of HDL-mediated RCT should be more important 
than the levels of HDL cholesterol in the bloodstream. Overly 
high levels of HDL cholesterol beyond the capacity of RCT 
may not be beneficial. Enhanced RCT and a higher turnover 
of HDL cholesterol may keep HDL cholesterol at appropriate 
levels. Dalcetrapib, a CETP modulator, and anacetrapib, a 
CETP inhibitor, are the most advanced agents and are in 
Phase III of clinical studies to reveal whether the agents 
are beneficial for the treatment of atherosclerosis-related 
diseases.19–22
CETP modulator, dalcetrapib  
(JTT -705)
Dalcetrapib (JTT-705) is the first small molecule that has 
succeeded in regulating CETP and demonstrating an anti-
atherogenic effect in vivo.23 Dalcetrapib is a benzenethiol 
derivative (Figure 2) that inhibits the CETP-mediated transfer 
of CE from HDL to apoB-containing lipoproteins in human 
plasma at an IC50 of 9 µM. The administration of dalcetrapib 
in cholesterol-fed rabbits at oral doses of 225 mg/kg/day for 
6 months caused a 90% increase in HDL cholesterol and 
decreased non-HDL cholesterol by 40%–50% compared 
to the control values. In the increased HDL cholesterol, 
HDL2 cholesterol increased by 170% and HDL3 cholesterol 
increased by 59%. Serum apolipoprotein A-I (apoA-I), which 
is the primary protein constituent of the HDL particle, also 
increased by 78%. As a result, dalcetrapib decreased the area 
of atherosclerotic lesions in the aortic arch by 70%, providing 
the first evidence that the small-molecule compound has a 
continuous inhibitory effect on CETP activity and retards 
the progression of atherosclerosis.
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Figure 1 Cholesterol transport.
Abbreviations: CETP, cholesteryl ester transfer protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein; VLDL, very low-density lipoprotein.
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The mechanism of action associated with dalcetrapib was 
examined using point mutants of recombinant human CETP. 
The C13S mutant, in which the cysteine at residue 13 was 
replaced by serine, was not inhibited by dalcetrapib, which 
suggests that the mechanism of action involved the formation 
of a disulfide bond between the thiol form of dalcetrapib and 
Cys13 of CETP. The disulfide bond between the thiol form 
of dalcetrapib and CETP is apparently reversible because the 
CETP inhibition induced by dalcetrapib decreased with time. 
The structure of CETP was determined at 2.2-Å resolution, 
revealing a 60-Å-long continuous tunnel filled with two 
hydrophobic CEs and plugged by an amphiphilic phosphati-
dylcholine at each end.24 The tunnel through the CETP – a 
tube with two distinct openings – allows the neutral lipid 
to pass through its entire length. In the through-the-tunnel 
model, the CETP potentially admits a neutral lipid from one 
opening and deposits a bound lipid from the opposite opening 
(Figure 3). Conformational changes are considered necessary 
so that the curvature of the concave surface of the CETP 
matches the different radius of the curvature of the lipopro-
teins, such as HDL, LDL, and VLDL. This model explains the 
CETP-mediated equimolar heteroexchange of CE and TG. 
The crystal structure also revealed that the Cys13 is located 
on the surface of the tunnel, which indicates that dalcetrapib, 
which is bound to the Cys13 of CETP, occupies part of the 
space for one CE and blocks the neutral lipid from binding or 
passing through the tunnel (Figure 4). The blockage caused 
by dalcetrapib impairs the function of CETP. Structurally, 
the dalcetrapib-bonded CETP should reduce its capacity of 
transport by 50% or more.
Interestingly, dalcetrapib inhibits the CETP-mediated 
heterotypic transfer of CE from HDL to apoB-containing 
OO
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Figure 2 Structures of dalcetrapib and its thiol form.
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Figure 3 The through-the-tunnel model.
Abbreviations: CETP, cholesteryl ester transfer protein; HDL, high-density lipoprotein; VLDL, very low-density lipoprotein.
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lipoproteins without inhibiting the CETP-mediated 
homotypic transfer of CE from HDL3 to HDL2 (Figure 5).25 
The CETP-mediated homotypic CE transfer generates larger 
HDL2 and smaller pre-β HDL from HDL3.25 Since this pro-
cess transfers CE along the RCT pathway, the partial CETP 
inhibition caused by dalcetrapib is considered more beneficial 
for CE clearance than complete CETP inhibition. In hamsters 
injected with 3H-labeled cholesterol-containing autologous 
macrophages, dalcetrapib (100 mg twice daily for 7 days) 
increased plasma HDL 3H-labeled cholesterol as well as the 
fecal elimination of 3H-labeled neutral sterols and 3H-labeled 
bile acids.25 The results indicate that dalcetrapib increases 
RCT and CE clearance.
Although the mechanism leading to partial CETP 
inhibition by dalcetrapib has not been elucidated, the 
function of dalcetrapib-bonded CETP is likely the key. 
The dalcetrapib-bonded CETP potentially holds one CE in 
the tunnel and transfers the CE from HDL3 to HDL2 differ-
ently to the through-the-tunnel model (Figure 6). The transfer 
is against the concentration gradient of CE. The reason why 
the dalcetrapib-bonded CETP can discriminate between 
the heterotypic transfer and the homotypic transfer may be 
because the dalcetrapib-bonded CETP cannot conform by 
attaching to the surface of apoB-containing lipoproteins, but 
it can conform by attaching to the surface of HDL particles. 
Dalcetrapib is considered a CETP modulator because of its 
unique effects on CETP functions.25
In the dal-VESSEL (dalcetrapib Phase IIb endothelial 
function) study, 476 patients with coronary heart disease 
or cardiovascular risk equivalents were randomized to 
600 mg/day of dalcetrapib or placebo in addition to their 
existing treatments for 36 weeks.26 Dacetrapib reduced 
CETP activity by 50% and increased HDL cholesterol 
levels by 31% without changing LDL cholesterol 
levels. In the dal-VESSEL study, dalcetrapib did not 
impair nitric-oxide-dependent endothelial functions, 
change markers of inflammation and oxidative stress, 
or increase blood pressure. The dal-PLAQUE (safety 
and efficacy of dalcetrapib on atherosclerotic disease 
using novel non-invasive multimodality imaging) study 
provided data on the effects of dalcetrapib on structural 
and functional markers for atherogenesis. In this study, 
130 patients with coronary heart disease or cardiovascular 
risk equivalents were randomly assigned to dalcetrapib 
600 mg/day or placebo in addition to statin or other LDL 
cholesterol-lowering drug treatment for 24 months.19 
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Figure 4 Bound lipids and dalcetrapib in the tunnel of CETP.
Abbreviation: CETP, cholesteryl ester transfer protein.
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Magnetic resonance imaging (MRI) was used to analyze the 
vessel wall structure and 18F-labeled fluorodeoxyglucose 
(18F-FDG) positron emission tomography (PET)/computed 
tomography (CT) to measure vessel wall inflammation. 
HDL cholesterol concentrations in the dalcetrapib group 
increased by 30.9% from baseline without changing LDL 
cholesterol and TG concentrations. Dalcetrapib did not 
increase inflammation in the vessel wall over 6 months 
compared with the placebo. Carotid vessel analysis of the 
18F-FDG-PET/CT data showed a 7% reduction in vascular 
inflammation over 6 months in the dalcetrapib group 
relative to the placebo group. Moreover, dalcetrapib did 
not increase plaque progression over 24 months compared 
with the placebo. MRI-driven change in the total vessel 
area was reduced in the dalcetrapib group compared with 
the placebo group, and the absolute change from baseline 
relative to placebo was −4.01 mm2. This trial suggested 
the possible beneficial vascular effects of dalcetrapib, but 
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Figure 5 The effects of dalcetrapib on CETP-mediated cholesterol transport.
Abbreviations: CETP, cholesteryl ester transfer protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein; VLDL, very low-density lipoprotein.
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Figure 6 Hypothetic homotypic transfer mediated by dalcetrapib-bonded CETP.
Abbreviations: CETP, cholesteryl ester transfer protein; HDL, high-density lipoprotein.
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the crucial question is whether the beneficial effects of 
dalcetrapib will result in reduced cardiovascular events. 
The dal-OUTCOMES (efficacy and safety of dalcetrapib 
in patients with recent acute coronary syndrome) study, 
which includes 15,600 patients, is currently testing the 
addition of dalcetrapib to standard medical therapy for the 
reduction of cardiovascular events. Phase III of the study 
will be completed by 2013.27
A series of 3,5-bis(trifluoromethyl) 
phenyl derivatives as CETP 
inhibitors
Torcetrapib
Torcetrapib, a 3,5-bis(trifluoromethyl)phenyl derivative, 
was the most advanced CETP inhibitor until its development 
was terminated due to its adverse effects. The ILLUMINATE 
(investigation of lipid-level management using coronary 
ultrasound to assess reduction of atherosclerosis by CETP 
inhibition and HDL elevation) study was prematurely 
terminated because of an increased cardiovascular event 
rate in patients receiving the CETP inhibitor, torcetrapib. 
In Phase III of the study, 15,067 patients at high risk for 
cardiovascular disease were randomly assigned to receive 
either 60 mg of torcetrapib plus atorvastatin, or placebo 
plus atorvastatin. Torcetrapib caused a 72.1% increase in 
HDL cholesterol and a 24.9% decrease in LDL cholesterol. 
Despite the favorable lipid changes in the torcetrapib 
group, the rate of major cardiovascular events increased 
by 25% and the rate of death from cardiovascular causes 
increased by 40%.28 Torcetrapib was also associated with an 
increase of 5.4 mmHg in systolic blood pressure. Currently, 
adverse events caused by torcerapib are considered to be 
molecule-specific and are not to relate to the mechanism 
of CETP inhibition. The RADIANCE (a pooled analysis 
of the rating atherosclerotic disease change by imaging 
with a new CETP inhibitor) and the ILLUMINATE studies 
indicated a relationship between increased blood pressure 
and thickening carotid vessel walls, as well as between 
renin-angiotensin-aldosterone system (RAAS) activation 
and risk of death.28–32 In contrast, it has been confirmed that 
other CETP inhibitors and dalcetrapib have no effect on the 
upregulation of genes, encoding components of the RAAS, 
increased concentration of mineralocorticoid hormones, or 
raised blood pressure.33,34
After finding a tetrazole derivative (Figure 7), which 
revealed that the carbamate moiety could be replaced with an 
amino-tetrazole ring and the tetrahydropyridine ring could be 
opened to acyclic structures, 3,5-bis(trifluoromethyl)phenyl 
derivatives lacking torcetrapib-specific adverse effects, such 
as anacetrapib and evacetrapib, were derived from torcerapib.35 
Figure 7 presents the main structural transition of the torce-
trapib series. Among the torcetrapib series of CETP inhibitors, 
the most advanced anacetrapib is in Phase III of a study and 
the second evacetrapib is in Phase II of a study.18,20,36
Anacetrapib
In contrast with dalcetrapib, anacetrapib inhibits the hetero-
typic CE transfer from HDL to LDL and the homotypic CE 
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Figure 7 Structural transition of 3,5-bis(trifluoromethy)phenyl derivatives as CETP inhibitors.
Abbreviation: CETP, cholesteryl ester transfer protein.
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transfer from HDL3 to HDL2 (Figure 8). Although the exact 
mechanism of CETP inhibition by the torcerapib series of 
compounds including anacetrapib has not been elucidated, 
the torcetrapib series of CETP inhibitors bind specifically 
to CETP with 1:1 stoichiometry and block all of the major 
transfer functions of plasma CETP by inducing a nonpro-
ductive complex between the transfer protein and HDL.37 
Anacetrapib demonstrated dose-dependent inhibition of 
pre-β HDL formation in vitro, and did not increase the fecal 
elimination of  3H-labeled neutral sterols and  3H-labeled 
bile acids in hamsters injected with 3H-labeled cholesterol-
containing autogous macrophages, despite increasing plasma 
HDL 3H-labeled cholesterol.25 This indicates that anacetrapib 
could not increase HDL-mediated RCT in hamsters despite 
a marked increase in plasma HDL cholesterol. Raised HDL 
cholesterol can be expected to enhance HDL-mediated RCT, 
but the inhibitory effect of anacetrapib on CETP-mediated 
homotypic CE transfer may block this enhancement. CETP-
mediated homotypic CE transfer may be more important for 
HDL-mediated RCT than expected. However, the clinical 
relevance of the results is unknown.
In contrast with torcetrapib, anacetrapib did not result 
in raised blood pressure in the Phase I or II studies and 
does not increase aldosterone synthesis in adrenal cortical 
cells.16,17,33,38 The safety of anacetrapib was further studied 
in the DEFINE (determining the efficacy and tolerability of 
CETP inhibition with anacetrapib) trial.20 In the DEFINE 
study, 1623 patients with coronary heart disease or who were 
at high risk for coronary heart disease were randomized to 
100 mg/day of anacetrapib or placebo in addition to statin 
treatment with or without other lipid-modifying therapy for 
18 months. In this study, anacetrapib increased HDL choles-
terol levels by 138% and decreased LDL cholesterol levels 
by 36%. The study confirmed that anacetrapib had no effect 
on electrolytes, aldosterone levels, or blood pressure. The 
adverse cardiovascular event levels did not differ between 
the anacetrapib and placebo groups.
The REVEAL (randomized evaluation of the effects 
of anacetrapib through lipid modification, a large-scale, 
randomized placebo-controlled trial of the clinical effects 
of anacetrapib among people with established vascular dis-
ease) cardiovascular outcome study, which includes 30,000 
patients, is currently testing whether anacetrapib will reduce 
the incidence of major coronary events (coronary mortality, 
myocardial infarction, and coronary revascularization) in 
patients with a history of cardiovascular disease who are 
undergoing statin therapy to lower LDL cholesterol.36 This 
Phase III study is expected to be completed by 2017.
Evacetrapib
Another CETP inhibitor, evacetrapib, showed a marked 
increase in HDL cholesterol and a decrease in LDL choles-
terol with no change in blood pressure or aldosterone levels. 
These results are derived from a 12-week Phase II study that 
included 398 patients with elevated LDL cholesterol or low 
LDL cholesterol levels. A daily dose of 500 mg of evacetrapib 
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Figure 8 The effects of anacetrapib on CETP-mediated cholesterol transport.
Abbreviations: CETP, cholesteryl ester transfer protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein; VLDL, very low-density lipoprotein.
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as monotherapy increased HDL cholesterol levels by 132% 
and decreased LDL cholesterol levels by 40%.18
Conclusion
Anacetrapib belongs to the torcetrapib series of CETP inhibi-
tors, but has no adverse cardiovascular effects in contrast 
with torcetrapib. Anacetrapib blocks the transfer functions of 
CETP and achieves a favorable plasma-lipids profile as well 
as a marked increase in HDL cholesterol and decrease in LDL 
cholesterol. Unexpectedly, anacetrapib does not increase 
RCT despite markedly increasing HDL cholesterol in vivo 
using a hamster model, although the clinical relevance of 
the result is unknown. Even if increased HDL cholesterol 
induced by anacerapib does not increase cholesterol clear-
ance via the HDL-mediated RCT pathway, the simultaneous 
decrease of LDL cholesterol induced by anacetrapib can be 
expected to improve the cardiovascular condition.
Dalcetrapib provided a relatively smaller increase in HDL 
cholesterol than anacetrapib did. This may be due to a higher 
turnover of HDL cholesterol, because the CETP modulator, 
dalcetrapib, does not inhibit CETP-mediated homotypic CE 
transfer and increases HDL-mediated RCT. It is worth noting 
the dynamics of cholesterol clearance rather than the levels 
of HDL cholesterol in the bloodstream. Abnormally high 
levels of HDL cholesterol could indicate a failure to enhance 
RCT and cholesterol clearance. Despite the smaller increase 
in plasma HDL cholesterol levels, dalcetrapib showed a 
reduction in vascular inflammation and structural vascular 
changes (plaque progression) in clinical studies.
The CETP modulator, dalcetrapib, and the CETP inhibi-
tor, anacetrapib, are currently in Phase III trials to test their 
effects on cardiovascular outcomes. Dalcetrapib can reveal 
the role of HDL cholesterol in reducing cardiovascular 
events, because dalcetrapib increases HDL cholesterol with-
out lowering LDL cholesterol. In contrast, the simultaneous 
decrease of LDL cholesterol by anacetrapib complicates 
the interpretation of the role of HDL cholesterol. However, 
anacetrapib can reveal the role of CETP in cardiovascular 
events.
Disclosure
The author is the coinventor of dalcetrapib, and an employee 
of JT Inc. JT Inc licensed-out JTT-705 (dalcetrapib) to 
F Hoffmann-La Roche Ltd.
References
1.  Bays H, Stein EA. Pharmacotherapy for dyslipidemia-current therapies 
and future agents. Expert Opin Pharmacother. 2003;4:1901–1938.
2.  Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High 
density lipoprotein as a protective factor against coronary heart disease. 
The Framingham Study. Am J Med. 1977;62:707–714.
3.  Jafri H, Alsheikh-Ali AA, Karas RH. Meta-analysis: statin therapy does 
not alter the association between low levels of high-density lipoprotein 
cholesterol and increased cardiovascular risk. Ann Intern Med. 2010;153: 
800–808.
4.  Arsenault BJ, Barter P, DeMicco DA, et al. Prediction of cardiovascular 
events in statin-treated stable coronary patients by lipid and nonlipid 
biomarkers. J Am Coll Cardiol. 2011;57:63–69.
5.  Johnsen SH, Mathiesen EB, Fosse E, et al. Elevated high-density lipo-
protein cholesterol levels are protective against plaque progression: a 
follow-up study of 1952 persons with carotid atherosclerosis the Tromsø 
study. Circulation. 2005;112:498–504.
Table 1 CETP modulator and inhibitors
Dalcetrapib Torcetrapib Anacetrapib Evacetrapib
Chemical class Benzenethiol 3,5-bis(CF3)phenyl 3,5-bis(CF3)phenyl 3,5-bis(CF3)phenyl
Effect on CETP Modulation  
(selective inhibition)
Complete inhibition Complete inhibition No data
  Heterotypic CE transfer Block Block Block No data
  Homotypic CE transfer No effect Block Block No data
RCT (fecal elimination of  
neutral sterols and bile acids)
Increase Slight increase No change No data
Clinical stage Phase III Termination Phase III Phase II
Clinical data
  HDL increase 31% 72% 138% 132%
  LDL decrease No change 25% 36% 40%
  Aldosterone levels No change Increase No change No change
  Blood pressure No change Increase No change No change
  Vascular inflammation Reduction (PET/CT) No data No data No data
  Plaque progression Reduction (MRI) No data No data No data
  Safety Safe Increased cardiovascular  
events and death
Safe Safe
Abbreviations: CF3, trifluoromethyl; CETP, cholesteryl ester transfer protein; CE, cholesteryl ester; RCT, reverse cholesterol transport; HDL, high-density lipoprotein; 
LDL, low-density lipoprotein; PET, positron emission tomography; CT, computed tomography; MRI, magnetic resonance imaging.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
330
ShinkaiVascular Health and Risk Management
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/vascular-health-and-risk-management-journal
Vascular Health and Risk Management is an international, peer-
reviewed journal of therapeutics and risk management, focusing on 
concise rapid reporting of clinical studies on the processes involved 
in the maintenance of vascular health; the monitoring, prevention and 
treatment of vascular disease and its sequelae; and the involvement of 
metabolic disorders, particularly diabetes. This journal is indexed on 
PubMed Central and MedLine. The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
Vascular Health and Risk Management 2012:8
  6.  Wei L, Murphy MJ, MacDonald TM. Impact on cardiovascular events 
of increasing high density lipoprotein cholesterol with and without lipid 
lowering drugs. Heart. 2006;92:746–751.
  7.  Rubins HB, Robins SJ, Collins D. et al. Gemfibrozil for the secondary 
prevention of coronary heart disease in men with low levels of high-
density lipoprotein cholesterol. N Engl J Med. 1999;341:410–418.
  8.  Shepherd J, Betteridge J, Van Gaal L, et al. Nicotinic acid in the 
management of dyslipidaemia associated with diabetes and metabolic 
syndrome: a position paper developed by a European Consensus Panel. 
Curr Med Res Opin. 2005;21:665–682.
  9.  Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res.1993;34: 
1255–1274.
  10.  Marcel YL, McPherson M, Hogue H, et al. Distribution and 
concentration of cholesteryl ester transfer protein in plasma of normo-
lipemic subjects. J Clin Invest. 1990;85:10–17.
  11.  Ha YC, Gorjatschko L, Barter PJ. Changes in the density distribution 
of pig high density lipoproteins during incubation in vitro. Influence 
of esterified cholesterol transfer activity. Atherosclerosis 1983;48: 
253–263.
  12.  Paromov VM, Morton RE. Lipid transfer inhibitor protein defines the 
participation of high-density lipoprotein subfractions in lipid transfer 
reactions mediated by cholesterol ester transfer protein (CETP). J Biol 
Chem. 2003;278:40859–40866.
  13.  Barter PJ, Brewer HB Jr, Chapman J, et al. Cholesteryl ester transfer 
protein. A novel target for raising HDL and inhibiting atherosclerosis. 
Arterioscler Thromb Vas Biol. 2003;23:160–167.
  14.  De Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al. Efficacy and 
safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, 
in humans: a randomized phase II dose–response study. Circulation. 
2002;105(21):2159–2165.
  15.  Kuivenhoven JA, De Grooth GJ, Kawamura H, et al. Effectiveness 
of inhibition of cholesteryl ester transfer protein by JTT-705 in 
combination with pravastatin in type II dyslipidemia. Am J Cardiol. 
2005;95:1085–1088.
  16.  Krishna R, Anderson MS, Bergman AJ, et al. Effect of the cholesteryl 
ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients 
with dyslipidaemia and on 24-h ambulatory blood pressure in healthy 
individuals: two double-blind, randomized placebo-controlled phase I 
studies. Lancet. 2007;370:1907–1914.
  17.  Bloomfield D, Carlson GL, Sapre A, et al. Efficacy and safety of the cho-
lesteryl ester transfer protein inhibitor anacetrapib as monotherapy and 
coadministered with atorvastatin in dyslipidemic patients. Am Heart J.   
2008;157(2):352–360.
  18.  Nicholls SJ, Brewer HB, Kastelein JJP, et al. Effects of the CETP 
inhibitor evacetrapib administered as monotherapy or in combination 
with statin on HDL and LDL cholesterol. A randomized controlled 
trial. JAMA. 2011;306(19):2099–2109.
  19.  Fayad ZA, Mani V, Woodward M, et al. Safety and efficacy of 
dalcetrapib on atherosclerotic disease using novel non-invasive multi-
modality imaging (dal-PLAQUE): a randomized clinical trial. Lancet. 
2011;378:1547–1559.
  20.  Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in 
patients with or at high risk for coronary heart disease. New Engl J 
Med. 2010;363(25):2406–2415.
  21.  Davidson MH. Update on CETP inhibition. J Clin Lipidology. 2010; 
4(5):394–398.
  22.  Miyares MA. Anacetrapib and Dalcetrapib: Two novel cholesteryl ester 
transfer protein inhibitors. Ann Pharmacother. 2011;45(1):84–94.
  23.  Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H. 
A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis 
in rabbits. Nature. 2000;406(6792):203–207.
  24.  Qui X, Mistry A, Ammirati MJ, et al. Crystal structure of cholesteryl 
ester transfer protein reveals a long tunnel and four bound lipid 
  molecules. Nat Struct Mol Biol. 2007;14(2):106–113.
  25.  Niesor EJ, Magg C, Ogawa N, et al. Modulating cholesteryl ester transfer 
protein activity maintains efficient pre-β-HDL formation and increases 
reverse cholesterol transport. J Lipid Res. 2010;51:3443–3454.
  26.  Lüscher T. Dalcetrapib passed test in dal-VESSEL: Raises HDL 
cholesterol but not blood pressure. European Society of Cardiology 
Congress; August 29, 2011. Paris.
  27.  Schwartz GG, Olsson AG, Ballantyne CM, et al. Rationale and design 
of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in 
patients with recent acute coronary syndrome. Am Heart J. 2009;158: 
896–901.
  28.  Barter PJ, Caulfield M, Eriksson M, el al. Effects of torcetrapib in 
patients at high risk for coronary events. N Engl J Med. 2007;357: 
2109–2122.
  29.  Rader DJ. Illuminating HDL – Is it still a viable therapeutic target?   
N Engl J Med. 2007;357:2180–2183.
  30.  Vergeer M, Bots ML, van Leuven SI, et al. Cholesteryl ester transfer 
protein inhibitor torcetrapib and off-target toxicity. A pooled analysis of 
the rating atherosclerotic disease change by imaging with a new CETP 
inhibitor (RADIANCE) trials. Circulation. 2008;118(25):2515–2522.
  31.  Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on 
carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med. 
2007;356:1620–1630.
  32.  Bots ML, Visseren FL, Evans GW, et al. Torcetrapib and carotid 
intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): 
a randomised, double-blind trial. Lancet. 2007;370:153–160.
  33.  Hu X, Dietz JD, Xia C, et al. Torcetrapib induces aldosterone and 
  cortisol production by an intracellular calcium-mediated mechanism 
independently of cholesteryl ester transfer protein inhibition. 
Endocrinology. 2009;150:2211–2219.
  34.  Stroes ES, Kastelein JJ, Benardeau A, et al. Dalcetrapib: no off-target 
toxicity on blood pressure or on genes related to the renin-angiotensin-
aldosterone system in rats. Br J Pharmacol. 2009;158:1763–1770.
  35.  Shinkai, H. Cholesteryl ester transfer protein inhibitors as high-density 
lipoprotein raising agents. Expert Opin Ther Patents. 2009;19(9): 
1229–1237.
  36.  Gutstein DE, Krishna R, Johns D, et al. Anacetrapib, a novel CETP 
inhibitor: pursuing a new approach to cardiovascular risk reduction. 
Clin Pharmacol Ther. 2012;91(1):109–122.
  37.  Clark RW, Ruggeri RB, Cunningham D, et al. Description of the 
torcetrapib series of cholesteryl ester transfer protein inhibitors, 
including mechanism of action. J Lipid Res. 2006;47:536–552.
  38.  Forrest MJ, Bloomfield D, Briscoe RJ, et al. Torcetrapib-induced blood 
pressure elevation is independent of cholesteryl ester transfer protein 
inhibition and is accompanied by an increase in circulating aldosterone 
levels. Br J Pharmacol. 2008;154:1465–1473.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
331
CETP modulator and inhibitors